A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiD<sup>TM</sup>II) for the treatment of cognitive impairment after mild traumatic brain injury.
- Published in:
- PLoS ONE, 2025, v. 20, n. 7, p. 1, doi. 10.1371/journal.pone.0310229
- By:
- Publication type:
- Article